Effect of Intravenous Lidocaine on Immediate Post-operative Pain, Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Placebo Controlled Trial
NCT ID: NCT04182828
Last Updated: 2019-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
120 participants
INTERVENTIONAL
2019-11-25
2020-11-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rectal Indomethacin Versus Intraperitoneal Lidocaine for Analgesia After Laparoscopic Cholecystectomy
NCT04964180
Synergistic Effect of Intravenous Lidocaine on Anesthetic Induction and Emergence in Patients Undergoing Laparoscopic Cholecystectomy or Gynecological Surgery
NCT07193836
Laparoscopic Cholecystectomy: General Anesthesia With Opioid Versus General Opioid Free Anesthesia
NCT02953210
Effect of Lidocaine Plus Dexmedetomidine Infusion on PONV
NCT03788018
Impact of Pyloric Injection of Magnesium Sulfate and Lidocaine Mixture on Outcome After Sleeve Gastrectomy
NCT03729505
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The clinical trial unit (CTU) will be responsible to prepare the study drug and placebo in the same volume, color, consistency and packaging and treatment allocation would be done by assigning the study drug and placebo numbers. The staff, patient and the anaesthetists will be blind by the drug allocation. Only the CTU will have the list of randomization and their treatment allocation.
All patient will be given general anesthesia as per standard of care. All patients will be pre-medicated with oral midazolam 7.5 mg one hour before operating room. Standard American Society of Anaesthesiologists (ASA) monitoring (NIBP, ECG, and Pulse Oximetry) will be applied. General anesthesia will be induced by Propofol 2 mg/kg, Nalbuphine 0.1mg/kg and Cis-Atracurium 0.2 mg/kg. Isoflurane 1% - 1.5% in a mixture of oxygen and air (50:50) will be used for maintenance of anesthesia. Before tracheal intubation, patients will receive intravenous bolus injection of the study drug in dose of 1.5mg/kg followed by the continuous infusion at the rate of 1.5mg/kg/hr. via standard computerized programmable infusion pump. The infusion will be continued throughout the surgery and will be stopped after extubation. After intubation, patients' minute ventilation will be adjusted to maintain normocapnia (end tidal CO2 35 - 40 mm of Hg). All patients will be given 1gm of intravenous Paracetamol after induction of anaesthesia. Supplemental analgesia, Nalbuphine 1mg, during surgery will be given if the heart rate and systolic blood pressure increases above 20% of respective baseline values and causes other than pain had been ruled out, which would be at the discretion of the primary anaesthetist. Prophylaxis for nausea and vomiting will be given by Dexamethasone 0.1mg/kg at induction of anaesthesia and Ondansetron 0.1mg/kg after the removal of gall bladder. At the end of surgery, residual neuromuscular blockade will be reversed by 0.05mg/kg of neostigmine and 0.5mg of glycopyrolate. The trachea will be extubated once the patient regained consciousness and then transferred to the post anesthesia care unit (PACU).
In the PACU, each patient will be assessed by the primary investigator for pain, nausea and vomiting at 15, 30, and 60 minutes. If the patient's pain will be equal to 4 or more on the numerical rating scale, he/she will be given Nalbuphine 1mg as a rescue analgesic. Likewise, if the patients has complain of nausea or vomiting, equal to or greater than 2 on Bellvile nausea score, he/she will be given Metoclopramide 10mg as rescue antiemetic. The analgesic and anti-emetic requirement in the ward for the first 6 hr. post-operatively will be recorded by the primary investigator.
The time of arrival at PACU will be recorded as "T1". The discharge time from PACU will also be recorded and would be declared as "T2". The time required for the patient to be discharged from the hospital will be recorded as "TD". TD will be the time when surgical team decides that patient can be discharged from the hospital. The difference between the length of stay in the hospital between the two groups will be calculated as total time spent (in HOURS) in the hospital "TT". It will be the sum of time interval between T1 to T2, and T2 to TD.
TT= (T1+T2+TD)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo Group(PG)
It will be normal saline 0.9%
Lidocaine
both the drugs will be prepared in same volume, color, consistency and appearance
Lidocaine Group(LG)
It will be lidocaine 2%
Lidocaine
both the drugs will be prepared in same volume, color, consistency and appearance
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lidocaine
both the drugs will be prepared in same volume, color, consistency and appearance
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All adults aged between 18 to 65 years
* ASA I and II
Exclusion Criteria
* Allergy to local anesthetic agents
* Patient with or history of arrhythmias
* Patients with SGPT greater than 35 IU/L for females and greater than 45 IU/L for males.
* Patients with chronic renal disease and creatinine greater than 1.5mg/dl.
* Chronic use of opioids
* The surgeries which were converted to open procedures.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aga Khan University Hospital, Pakistan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Muhammad Umer Slote
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. M. Umer Slote, MBBS
Role: PRINCIPAL_INVESTIGATOR
Aga Khan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aga Khan University Hospital
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-1558-5378
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.